# Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

> **NCT05399992** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 847 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

- **OTHER:** Inclisiran

## Key facts

- **NCT ID:** NCT05399992
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-12
- **Primary completion:** 2026-10-05
- **Final completion:** 2026-10-05
- **Target enrollment:** 847 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399992, "Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05399992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*